ES2270347T3 - Composiciones farmaceuticas estabilizadas de safingol y metodos de utilizacion de las mismas. - Google Patents

Composiciones farmaceuticas estabilizadas de safingol y metodos de utilizacion de las mismas. Download PDF

Info

Publication number
ES2270347T3
ES2270347T3 ES04712898T ES04712898T ES2270347T3 ES 2270347 T3 ES2270347 T3 ES 2270347T3 ES 04712898 T ES04712898 T ES 04712898T ES 04712898 T ES04712898 T ES 04712898T ES 2270347 T3 ES2270347 T3 ES 2270347T3
Authority
ES
Spain
Prior art keywords
solution
emulsion
sphingolipid
dihydrosphingosine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04712898T
Other languages
English (en)
Spanish (es)
Inventor
Barry James Maurer
Patrick C. Reynolds
Rao B. Vishnuvajjala
Shanker Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Los Angeles
Childrens Hospital Los Angeles Research Institute
Original Assignee
Children's Hospital of Los Angeles
Childrens Hospital Los Angeles Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Los Angeles, Childrens Hospital Los Angeles Research Institute filed Critical Children's Hospital of Los Angeles
Application granted granted Critical
Publication of ES2270347T3 publication Critical patent/ES2270347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES04712898T 2003-02-21 2004-02-19 Composiciones farmaceuticas estabilizadas de safingol y metodos de utilizacion de las mismas. Expired - Lifetime ES2270347T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21
US449536P 2003-02-21

Publications (1)

Publication Number Publication Date
ES2270347T3 true ES2270347T3 (es) 2007-04-01

Family

ID=32927531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04712898T Expired - Lifetime ES2270347T3 (es) 2003-02-21 2004-02-19 Composiciones farmaceuticas estabilizadas de safingol y metodos de utilizacion de las mismas.

Country Status (9)

Country Link
US (1) US7476692B2 (cg-RX-API-DMAC10.html)
EP (1) EP1594488B1 (cg-RX-API-DMAC10.html)
JP (2) JP4842800B2 (cg-RX-API-DMAC10.html)
AT (1) ATE331507T1 (cg-RX-API-DMAC10.html)
CA (1) CA2516399C (cg-RX-API-DMAC10.html)
DE (1) DE602004001393T2 (cg-RX-API-DMAC10.html)
ES (1) ES2270347T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA05008860A (cg-RX-API-DMAC10.html)
WO (1) WO2004075834A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013016B8 (en) 2006-03-29 2014-10-08 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
WO2015013566A1 (en) * 2013-07-25 2015-01-29 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
CA2234968A1 (en) * 1995-10-18 1997-04-24 Mary Kay Inc. Topically applied, structural cellulite treatments
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6352844B1 (en) * 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
US7846969B2 (en) 2001-12-10 2010-12-07 Kao Corporation Ceramide emulsions
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
JP2005538156A (ja) * 2002-09-05 2005-12-15 ガルデルマ・ソシエテ・アノニム 爪塗布用溶液

Also Published As

Publication number Publication date
CA2516399A1 (en) 2004-09-10
JP4842800B2 (ja) 2011-12-21
JP2011126886A (ja) 2011-06-30
US20050187186A1 (en) 2005-08-25
DE602004001393D1 (de) 2006-08-10
JP2006518743A (ja) 2006-08-17
DE602004001393T2 (de) 2007-06-14
US7476692B2 (en) 2009-01-13
WO2004075834A2 (en) 2004-09-10
EP1594488B1 (en) 2006-06-28
CA2516399C (en) 2013-05-14
MXPA05008860A (es) 2005-10-05
ATE331507T1 (de) 2006-07-15
WO2004075834A3 (en) 2005-03-24
EP1594488A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
JP6404242B2 (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
ES2813340T3 (es) Método de tratamiento del cáncer
ES2909741T3 (es) Tratamiento del cáncer
BR102020023664A2 (pt) Composições compreendendo canabidiol e flavononas
CN112789059A (zh) 氨基酸类营养素的应用以及包含它的药物组合物
MX2013005196A (es) Metodos para tratamiento del cancer.
US20240058267A1 (en) Slurry and solution compositions
WO2012004438A1 (es) Una formulación farmacéutica inyectable de melfalano
BR112020003349A2 (pt) composições e métodos para modular o crescimento capilar
US20220023288A1 (en) Pharmaceutical solution for oral dosage
EP2956131B1 (en) Treatment of klebsiella pneumoniae with liposomally formulated glutathione
JP2011126886A (ja) サフィンゴールの医薬組成物およびその使用方法
CN110870869A (zh) 包含糖类营养素和常规无效化合物的药物组合物及其应用
BR112020009141A2 (pt) método para tratar câncer de mama num indivíduo
CN110870858A (zh) 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用
JP2025532719A (ja) 腫瘍血管破壊用医薬組成物
CN112438942A (zh) 包含碱化剂及其协同物的药物组合物及其应用
CN110870918A (zh) 包含氨基酸类营养素和抗肿瘤化疗药物的药物组合物及其应用
WO2023215323A1 (en) Intranasal baclofen
US20060142254A1 (en) Antipyretic preparation containing xylitol
BRPI0713094A2 (pt) métodos de administração de droga
JP2011513378A (ja) ベリノスタットの長期持続注入を用いた治療方法
ES2990173B2 (es) Complejo de inclusion cuaternario de hidroxitirosol, triptofano, arginina y gluconato de zinc, metodo de obtencion y uso
CN113230420A (zh) 包含亚甲蓝类活体染料的水基乳剂、该乳剂的应用以及包含该乳剂的药物组合物
JP6924431B2 (ja) ヒトを除く哺乳動物への薬剤の投与方法